Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does LOPERAMIDE Cause Malignant neoplasm progression? 82 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 82 reports of Malignant neoplasm progression have been filed in association with LOPERAMIDE (Anti-diarrheal). This represents 0.5% of all adverse event reports for LOPERAMIDE.

82
Reports of Malignant neoplasm progression with LOPERAMIDE
0.5%
of all LOPERAMIDE reports
15
Deaths
38
Hospitalizations

How Dangerous Is Malignant neoplasm progression From LOPERAMIDE?

Of the 82 reports, 15 (18.3%) resulted in death, 38 (46.3%) required hospitalization, and 2 (2.4%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for LOPERAMIDE. However, 82 reports have been filed with the FAERS database.

What Other Side Effects Does LOPERAMIDE Cause?

Drug ineffective (3,207) Diarrhoea (1,909) Constipation (1,614) Off label use (1,378) Incorrect dose administered (1,178) Drug abuse (1,088) Nausea (997) Intentional product use issue (871) Overdose (857) Toxicity to various agents (753)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which LOPERAMIDE Alternatives Have Lower Malignant neoplasm progression Risk?

LOPERAMIDE vs LOPINAVIR LOPERAMIDE vs LOPINAVIR\RITONAVIR LOPERAMIDE vs LOPRAZOLAM LOPERAMIDE vs LORATADINE LOPERAMIDE vs LORATADINE\PSEUDOEPHEDRINE

Related Pages

LOPERAMIDE Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression LOPERAMIDE Demographics